Company Mission

Our mission is to treat as many cancer patients as possible with the only one-time one-week cancer treatment.

We intend to develop a cancer immunotherapy specifically targeting cancer cells resistant to prior treatments. We believe we can build upon the current success of checkpoint inhibitors and modified T-cell therapies to achieve higher rates of clinical response while maintaining patient safety.